{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:46:43Z","timestamp":1794023203646,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-18-13805"],"award-info":[{"award-number":["ESR-18-13805"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["CA15-3"],"award-info":[{"award-number":["CA15-3"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.esmoop.2024.102235","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T17:40:15Z","timestamp":1707154815000},"page":"102235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-6289","authenticated-orcid":false,"given":"G.A.","family":"Martens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Demol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4608-1101","authenticated-orcid":false,"given":"F.","family":"Dedeurwaerdere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Breyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-9325","authenticated-orcid":false,"given":"K.","family":"De Smet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-6833","authenticated-orcid":false,"given":"P.","family":"De Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Smet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2024.102235_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102235_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","article-title":"International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer","volume":"22","author":"Lin","year":"2013","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102235_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102235_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer-European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102235_bib5","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"issue":"17","key":"10.1016\/j.esmoop.2024.102235_bib6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jama.281.17.1586","article-title":"Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up","volume":"281","author":"Palli","year":"1999","journal-title":"J\u00a0Am Med Assoc"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102235_bib7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators","volume":"271","year":"1994","journal-title":"J\u00a0Am Med Assoc"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102235_bib8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102235_bib9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.102235_bib10","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102235_bib11","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-18-2521","article-title":"Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial","volume":"25","author":"Rothe","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102235_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102235_bib13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102235_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin Chem"},{"issue":"28","key":"10.1016\/j.esmoop.2024.102235_bib15","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.102235_bib16","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/acs.analchem.2c00446","article-title":"Real-time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: feasibility and cross-validation with NGS","volume":"94","author":"Callens","year":"2022","journal-title":"Anal Chem"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102235_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102235_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41416-021-01422-w","article-title":"The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer","volume":"125","author":"Davidson","year":"2021","journal-title":"Br J Cancer"},{"issue":"27","key":"10.1016\/j.esmoop.2024.102235_bib19","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.22.01063","article-title":"Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update","volume":"40","author":"Henry","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102235_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003363","article-title":"Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: a cohort study","volume":"17","author":"Zivanovic Bujak","year":"2020","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102235_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdz085","article-title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","volume":"30","author":"Hrebien","year":"2019","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2024.102235_bib22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102235_bib23","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.102235_bib24","article-title":"Circulating tumor DNA for breast cancer: review of active clinical trials","volume":"32","author":"Baksh","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102235_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11864-020-00783-3","article-title":"Precision medicine for breast cancer utilizing circulating tumor DNA: it is in the blood","volume":"21","author":"Miller","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.102235_bib26","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102235_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:49:10Z","timestamp":1778834950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2059702924000036"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102235","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102235"}}